Crescendo Biologics

Home
About Us
Our Science
- Humabody^® V_H Platform
News & Events
- Press Releases
- Publications
Contact Us
LinkedIn
Twitter

Contact Us

Home
About Us
Our Science
- Humabody^® V_H Platform
News & Events
- Press Releases
- Publications

Home
About Us
Our Science
- Humabody^® V_H Platform
News & Events
- Press Releases
- Publications
Contact Us
LinkedIn
Twitter

Crescendo CEO says Takeda’s decision to exercise licence option is validation of its immunotherapy platform

Crescendo CEO says Takeda’s decision to exercise licence option is validation of its immunotherapy platform

APM Health Europe

Post navigation

Previous PostPrevious 50 Movers & Shakers in BioBusiness 2018

Next PostNext A Snapshot of Crescendo Biologics

Search for:

Recent Posts

Crescendo Biologics enters pre-clinical collaboration with Orano Med to explore Targeted Alpha Therapy
Hello world!
Clinical Development
Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody® therapeutic
Chief Medical Officer

Recent Comments

Archives

July 2020
May 2020
February 2020
January 2020
October 2019
September 2019
July 2019

Categories

Front Page
In the News
PR & News
Uncategorised
Videos

Meta

Log in
Entries feed
Comments feed
WordPress.org

Humabody^® and Multibody^® are registered trademarks of Crescendo Biologics Limited.
Privacy and Cookies Notice Cambridge Web Design

We use cookies to give you a better experience on our website. To find out more, and to manage your preferences, please consult our Privacy and Cookie Notice.